Revance Therapeutics Inc. (RVNC)
3.65
0.00 (0.00%)
At close: Feb 05, 2025, 3:59 PM
Revance Therapeutics Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Net Income | -323.99M | -356.42M | -281.31M | -282.09M | -159.43M | -142.57M | -120.59M | -89.27M | -73.48M | -62.92M | -52.45M | -58.26M | -44.86M |
| Depreciation & Amortization | 13.69M | 39.15M | 19.85M | 10.25M | 2.91M | 1.73M | 1.47M | 1.45M | 2M | 2.05M | 1.88M | 1.78M | 1.98M |
| Stock-Based Compensation | 47.81M | 52.34M | 43.43M | 36.45M | 17.92M | 16.27M | 13.23M | 11.95M | 12.39M | 6.53M | 548K | 79K | 273K |
| Other Working Capital | -19.53M | 20.11M | 2.85M | 29.29M | 34.63M | 51.15M | 3.84M | 1.81M | 3.22M | 240K | -6.05M | -8.15M | 570K |
| Other Non-Cash Items | 89.79M | 70.72M | 1.17M | 19.63M | 810K | 175K | 176K | 2.41M | 388K | -6.29M | 6.46M | 23.33M | 14.74M |
| Deferred Income Tax | n/a | n/a | 89K | -2.72M | -2.65M | -2.57M | 3.93M | 10.88M | 512K | 8.71M | -1.34M | 1.28M | -480K |
| Change in Working Capital | -43.88M | 665K | -4.77M | 39.97M | 34.27M | 22.72M | 6.44M | 2.76M | 2.52M | -3.16M | -2.85M | -7.13M | -66K |
| Operating Cash Flow | -216.57M | -193.55M | -221.54M | -178.5M | -106.16M | -104.25M | -95.34M | -59.83M | -55.67M | -55.07M | -47.76M | -38.91M | -28.41M |
| Capital Expenditures | -6.89M | -23.01M | -18.07M | -4.22M | -3.24M | -7.09M | -2.63M | -3.47M | -3.33M | -6.97M | -6.48M | -319K | -150K |
| Acquisitions | n/a | 19.8M | 7.7M | -818K | 8K | 100K | 100K | 1.8M | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | -263.92M | -347.97M | -183.59M | -259.3M | -331.36M | -314.91M | -36.03M | -280.68M | -54.09M | n/a | n/a | n/a | n/a |
| Sales Maturities Of Investments | 385.43M | 232.18M | 172M | 276.47M | 317M | 213.44M | 157.44M | 208.65M | 1M | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | -4.88M | -19.8M | -7.7M | 17.05M | -14.36M | 1.44M | -100K | -1.8M | 75K | 75K | 75K | 75K | 75K |
| Investing Cash Flow | 109.74M | -138.8M | -29.66M | 12.13M | -17.59M | -107.03M | 118.79M | -75.5M | -56.34M | -6.9M | -6.4M | -244K | -75K |
| Debt Repayment | 30.16M | 87.05M | n/a | 287.5M | n/a | -932K | -3.64M | -3.54M | 4.58M | -5.79M | 13.33M | 13.61M | 54.07M |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | -2.21M | n/a | -507K | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 6.22M | -3.37M | 8.16M | -39.96M | -1.18M | 2.71M | 3.35M | 899K | 1.76M | 333K | 40.66M | 7K | n/a |
| Financial Cash Flow | 136.57M | 331.69M | 29.87M | 331.48M | 221.66M | 1.78M | 195.94M | -2.64M | 142.59M | 229.09M | 53.99M | 13.62M | 54.07M |
| Net Cash Flow | 29.73M | -652K | -221.33M | 165.11M | 97.9M | -209.49M | 219.39M | -137.97M | 30.58M | 167.12M | -169K | -25.54M | 25.58M |
| Free Cash Flow | -223.46M | -216.56M | -239.61M | -182.72M | -109.4M | -111.34M | -97.97M | -63.3M | -59M | -62.05M | -54.23M | -39.23M | -28.56M |